558 related articles for article (PubMed ID: 28274140)
61. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
62. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
63. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
64. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
Zhang L; Zhang M; Zhang Y; Tong N
Sci Rep; 2016 Jan; 6():18904. PubMed ID: 26742577
[TBL] [Abstract][Full Text] [Related]
66. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
Barrett A; Boye KS; García-Pérez LE; Giorgino F; Guerci B; Füchtenbusch M; Yu M; Sapin H; Dib A; Heitmann E; Federici MO; Lebrec J
J Med Econ; 2024; 27(1):866-879. PubMed ID: 38963346
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
Frias JP; Wynne AG; Matyjaszek-Matuszek B; Bartaskova D; Cox DA; Woodward B; Li YG; Tham LS; Milicevic Z
Diabetes Obes Metab; 2019 Sep; 21(9):2048-2057. PubMed ID: 31050143
[TBL] [Abstract][Full Text] [Related]
68. Once-weekly glucagon-like peptide 1 receptor agonists.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
[TBL] [Abstract][Full Text] [Related]
69. Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
Bailey TS
J Fam Pract; 2018 Jun; 67(6 suppl):S14-S24. PubMed ID: 29912997
[TBL] [Abstract][Full Text] [Related]
70. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
Grunberger G; Forst T; Fernández Landó L; Pechtner V; Shaginian R; Jia N; Gough S
Diabet Med; 2016 Mar; 33(3):391-4. PubMed ID: 26179454
[TBL] [Abstract][Full Text] [Related]
71. GLP-1 Agonists in Type 1 Diabetes Mellitus.
Janzen KM; Steuber TD; Nisly SA
Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
[TBL] [Abstract][Full Text] [Related]
72. Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.
Kutoh E; Hayashi J; Kuto AN
Endocr Regul; 2019 Jul; 53(3):187-190. PubMed ID: 31517629
[TBL] [Abstract][Full Text] [Related]
73. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Ericsson Å; Fridhammar A
J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
[No Abstract] [Full Text] [Related]
74. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL
J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929
[TBL] [Abstract][Full Text] [Related]
75. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
76. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
Dungan KM; Raz I; Skrivanek Z; Sealls W; Fahrbach JL
Diabetes Obes Metab; 2016 Jan; 18(1):49-55. PubMed ID: 26362460
[TBL] [Abstract][Full Text] [Related]
77. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
[TBL] [Abstract][Full Text] [Related]
78. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
Bzowyckyj A
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488
[TBL] [Abstract][Full Text] [Related]
79. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
[TBL] [Abstract][Full Text] [Related]
80. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]